LONDON, Jan. 12, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the successful introduction of its new field sales operations and inventory automation solution in the US in partnership with Movemedical. The new platform is designed to deliver a more simplified and efficient way for field sales reps to manage their daily inventory operations - ultimately helping them better serve their surgeon customers.
Before the Movemedical solution was introduced, inventory management processes lacked the automation and transparency needed to align with healthcare facility requirements. This new solution will now enable better patient-matched logistics, helping Smith+Nephew deliver industry leading customer service. The sales force and operations teams will benefit from real-time data enabling smooth matching of customer requirements and product availability.
"The Movemedical solution will help ensure that the right product gets to the right customer – and the right patient – through the provision of clean and accurate data in real-time, empowering our teams to make faster and better decisions," said Skip Kiil, Global President of Orthopaedics at Smith+Nephew. "We were able to roll out the program to our entire US Orthopaedic sales force in just over one week, and in the middle of a very busy selling period. This underscores the platform's ease of integration and the execution of Movemedical's team."
"The Movemedical goal is always to partner with, and solve, our client's biggest challenges," said Bo Molozcnik, CEO of Movemedical. "The team at Smith+Nephew is progressive and innovative; they want to change the industry and we are lucky to be the technology partner that helps enable their ambition."
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
Movemedical is the world's leading software solution for enterprise medical device field inventory optimization and sales enablement. As the industry authority on integration and automation, Movemedical's comprehensive SaaS platform helps their partners with digital transformation of the inventory supply chain. This intelligent cloud platform has been successfully integrated into over 20 enterprise ERP instances and coordinated over 10 million surgeries worldwide. This unmatched experience, combined with its clean, modern, easy-to-use mobile and web interfaces, have all contributed to an industry-high 98% user adoption. By continually investing in forward-thinking technology and innovation, they inspire the industry to improve processes, reduce loss, increase visibility, and enable greater growth in the field. As a 10-year-old San Diego-based company operating in 47 counties worldwide, Movemedical is privately held, self-sustaining, and ready for the next global partnership opportunity. For more information about Movemedical, please visit www.movemedical.com and follow us on LinkedIn.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc